Who are Propofol-Lipuro's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Sevoflurane, Sufentanil, intravenous sedation with propofol, Propofol induced sedation, Auris-Sedina, propofol (drug), Remifentanil and/or propofol.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/propofol-lipuro.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Propofol-Lipuro — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Propofol-Lipuro (Propofol-Lipuro) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: GABA receptor agonist. Area: Anesthesiology.

phase 3 GABA receptor agonist GABA_A receptor Anesthesiology Small molecule Live · refreshed every 30 min

Target snapshot

Propofol-Lipuro (Propofol-Lipuro) — University Hospital, Grenoble. Propofol-Lipuro is a short-acting sedative-hypnotic agent that induces and maintains anesthesia by enhancing inhibitory neurotransmission mediated by GABA.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Propofol-Lipuro TARGET	Propofol-Lipuro	University Hospital, Grenoble	phase 3	GABA receptor agonist	GABA_A receptor
Sevoflurane, Sufentanil	Sevoflurane, Sufentanil	University of Saskatchewan	phase 3	General anesthetic, Opioid analgesic	GABA_A receptor, Mu-opioid receptor
intravenous sedation with propofol	intravenous sedation with propofol	University Hospital, Clermont-Ferrand	phase 3	GABA_A receptor agonist	GABA_A receptor
Propofol induced sedation	Propofol induced sedation	Centre Hospitalier Universitaire de Saint Etienne	phase 3	GABA_A receptor agonist	GABA_A receptor
Auris-Sedina	Auris-Sedina	Laboratorios Osorio de Moraes Ltda.	phase 3	Benzodiazepine	GABA_A receptor
propofol (drug)	propofol (drug)	B. Braun Melsungen AG	phase 3	GABA receptor agonist	GABA_A receptor
Remifentanil and/or propofol	Remifentanil and/or propofol	Alder Hey Children's NHS Foundation Trust	phase 3	Opioid analgesic, Sedative-hypnotic	Opioid receptors, GABA_A receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (GABA receptor agonist class)

Amsterdam UMC, location VUmc · 1 drug in this class
B. Braun Melsungen AG · 1 drug in this class
Impax Laboratories, LLC · 1 drug in this class
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · 1 drug in this class
University Hospital, Grenoble · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Propofol-Lipuro — Competitive Intelligence Brief. https://druglandscape.com/ci/propofol-lipuro. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing